Patrys Bets on Reformulation Over Reinvention

Patrys joins KapitaList to discuss RLS-2202, its planned Phase 1A study & how the FDA 505(b)(2) pathway could reshape development risk...

related topics

Share To

Featured content

Related stories

SCROLL TO TOP